All In Biotech

Drug Trial Radar · NCT03929666

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

74

Actual

Start

Aug 22, 2019

Primary completion

Aug 30, 2025

Study completion Aug 30, 2025

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Apr 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).

Conditions

  • HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Interventions

  • ZW25 (Zanidatamab)Drug

    * Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC) * Part 2: RD identified in Part 1

  • CapecitabineDrug

    Administered orally twice daily (PO bid)

  • CisplatinDrug

    Administered IV

  • FluorouracilDrug

    Administered IV

  • LeucovorinDrug

    Administered IV

  • OxaliplatinDrug

    Administered IV

  • BevacizumabDrug

    Administered IV

  • GemcitabineDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)Time frame: Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
  2. Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
  3. Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
  4. Confirmed Objective Response Rate (ORR) (Parts 1 and 2)Time frame: From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • University of Chicago

    Chicago, Illinois

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Centro de Investigacion Clinica SAGA

    Santiago, Chile

  • Icegclinic Research & Care

    Santiago, Chile

  • CECIM Biocinetic

    Santiago, Chile

  • Centro Internacional de Estudios Clínicos

    Santiago, Chile

  • Pusan National University

    Busan, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.